[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100635901":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":12,"locations":18,"responsibleParty":31,"collaborators":10,"id":33,"slug":10,"hasResults":34,"nctId":35,"briefTitle":36,"officialTitle":37,"acronym":10,"eligibilityCriteria":38,"healthyVolunteers":34,"sex":39,"minAge":40,"maxAge":10,"enrollmentInfo":41,"targetDuration":10,"studyType":44,"phases":10,"briefSummary":45,"conditions":46,"keywords":49,"overallStatus":55,"whyStopped":10,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":60,"completionDateStruct":61,"leadSponsor":63,"locationsCount":64},{"fullName":5,"class":6},"Daewoong Pharmaceutical Co. LTD.","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"Fexuclue Treatment Group",null,"Patients requiring prevention of NSAIDs-induced peptic ulcer who are prescribed Fexuclue Tablet 20 mg in routine clinical practice.",[13],{"name":14,"role":15,"phone":16,"phoneExt":10,"email":17},"SoHeui Kim","CONTACT","82-10-2994-5887","2210325@daewoong.co.kr",[19],{"facility":20,"status":10,"city":21,"state":10,"zip":10,"country":22,"countryCode":10,"cosmosGeoPoint":23,"geoPoint":28,"contacts":29},"Multiple centers in Republic of Korea","Seoul","South Korea",{"type":24,"coordinates":25},"Point",[26,27],126.9784,37.566,{"lat":27,"lon":26},[30],{"name":14,"role":15,"phone":16,"phoneExt":10,"email":17},{"type":32,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100635901",false,"NCT07558707","Fexuclue for Prevention of NSAIDs-Induced Peptic Ulcer in Real-World Practice","A Prospective, Multi-Center, Observational Study to Evaluate the Efficacy and Safety of Fexuclue Tablet 20 mg in Patients Requiring NSAIDs-Induced Peptic Ulcer Prevention","Inclusion Criteria:\n\n* Adults aged ≥19 years\n* Patients requiring NSAIDs therapy\n* Patients requiring prevention of NSAIDs-induced peptic ulcer\n* Patients prescribed Fexuclue Tablet 20 mg\n* Patients who provide written informed consent\n\nExclusion Criteria:\n\n* Hypersensitivity to Fexuclue or its components\n* Severe hepatic impairment\n* Pregnant or breastfeeding women\n* Patients considered inappropriate by investigator","ALL","19 Years",{"count":42,"type":43},7000,"ESTIMATED","OBSERVATIONAL","This study is a prospective, multi-center, observational study to evaluate the efficacy and safety of Fexuclue Tablet 20 mg in patients requiring prevention of NSAIDs-induced peptic ulcer in real-world clinical practice in Korea.\n\nPatients receiving NSAIDs and requiring gastroprotective therapy will be enrolled and followed prospectively. The study will assess patient-reported outcomes (PROs) related to gastrointestinal symptoms, as well as safety outcomes.",[47,48],"Peptic Ulcer","NSAID-Induced Peptic Ulcer",[50,51,52,53,54],"NSAIDs","Fexuprazan","PRO","Real-World","Peptic Ulcer Prevention","NOT_YET_RECRUITING","2026-04-27",{"date":58,"type":59},"2026-04-30","ACTUAL",{"date":58,"type":43},{"date":62,"type":43},"2027-12-31",{"name":5,"class":6},1]